| Home Market Dynamics Macro Trends Sector Trends Company Insights AI Investing Strategies Sign Up Login |
| Recent significant developments indicate robust activity within the biotechnology sector, particularly highlighted by Jazz Pharmaceuticals expanding its rare epilepsy portfolio through an acquisition. The sector is also underscored by strong representation in terms of FDA approvals and advancements in clinical trials, enhancing investor confidence. Interest in biotech investments is further reflected in discussions about stock movements and the overall healthcare ETF market. These factors suggest an optimistic outlook for growth in innovative biopharma solutions. The price action of Biotechnology (IBB) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The trend sentiment at 0.9 is bullish. The market sentiment at 0.2 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.IBB is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for Biotechnology sector is at 0.3, and the negative at -0.1 on 2026-08-15. The forces of Sector Price Trend (0.9), Broad Market Trend (0.7), Market Risk Appetite (0), Option Sentiment (0), and Price Level Sentiment (0) will drive up the price. The forces of Valuation Sentiment (-0.2), and Sentiment towards Fundamentals (-0.3) will drive down the price. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on IBB trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
Sign up to reveice Sector Rotation Notification
| IBB | ||||||||||||||||
| Date | Attention | Price | StdDev | Price Level | RSI | Hourly RSI | Change | 10 Day Trend | Trend Sentiment | Hourly Trend Sentiment | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-15 | 1%(0.1%) | 0.9 | 0.2 | -0.3 | 2.5 | |||||||||||
| 2026-08-14 | 0%(0%) | 198.05 | 2.51% | 80 | 68 | 28 | -0.53% | 0.57% | 0.9 | -0.1 | 0.7% | 0.2 | Wait | 50% | -0.2 | -0.5 |
| 2026-08-13 | 0%(0%) | 199.1 | 2.41% | 89 | 71 | 26 | -0.72% | 0.47% | 1.2 | -0.2 | 0.3% | 0.3 | Wait | 50% | 0.6 | -0.5 |
| 2026-08-12 | 0%(0%) | 200.54 | 2.24% | 103 | 74 | 52 | 0.34% | 0.62% | 1.4 | 0 | 0.3% | 0.3 | Wait | 50% | 1.2 | -0.5 |
| 2026-08-11 | 0%(0%) | 199.86 | 1.98% | 109 | 75 | 47 | -0.02% | 0.47% | 1.3 | 0.1 | 0.6% | 0.3 | Wait | 50% | 1.1 | 7.5 |
| 2026-08-10 | 0%(0%) | 199.89 | 1.67% | 124 | 69 | 84 | 1.16% | 0.63% | 1.7 | 0.4 | 1.4% | 0.8 | Long | 70% | 1.5 | -0.5 |
| 2026-08-09 | 0%(0%) | 1.3 | 0.9 | 2 | -0.5 | |||||||||||
| 2026-08-08 | 0%(0%) | 1.3 | 0.9 | 2.1 | -0.5 | |||||||||||
| 2026-08-07 | 0%(0%) | 197.6 | 1.23% | 133 | 70 | 85 | 2.56% | 0.48% | 1.3 | 0.7 | 1.1% | 0.7 | Wait | 50% | 2 | 7.5 |
| 2026-08-06 | 0%(0.1%) | 192.67 | 0.89% | 101 | 56 | 57 | 0.47% | 0.21% | 0.3 | 0.3 | 0.6% | 0.3 | Wait | 50% | 1 | 7.5 |
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | ||||||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | ||||||||||||||||
| Analysis | ||
| ● Rules, Risk & Reward: How Regulation Is Shaping Biotech (IBB) Sun. Oct 5, 2025 | ||
| ● A Summary of Recent Product/Service Development in Biotech Sector Sun. Oct 5, 2025 | ||
| ● Biotech Earnings Check-In: Where Strength Is Building (and Where It Isn’t) Sun. Oct 5, 2025 | ||
| Market News | ||
| 1 (3) Regeneron Pharmaceuticals Inc (REGN) Biotech Stocks Facing FDA Decision In August 2026 7/31/2026 9:13:52 AM Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 7/30/2026 6:56:59 AM Regeneron Pharma Q2 GAAP EPS $12.23; Non-GAAP EPS $14.29 7/30/2026 6:33:40 AM Biotech Stocks Facing FDA Decision In August 2026 7/27/2026 8:09:55 AM REGENXBIO Rises In Premarket As FDA Says No New Studies Needed For NAVSUNLI BLA Resubmission 6/22/2026 8:51:47 AM Sensorion Advances SENS-601 For GJB2 Hearing Loss And Discontinues SENS-501 Trials; Stock Down 6/10/2026 6:28:21 AM Regeneron Antibody Maftivimab Recommended By WHO For Ebola Trials 5/29/2026 2:01:07 AM WHO Recommends Regeneron's Ebola Antibody For Bundibugyo Outbreak Use 5/28/2026 10:56:12 PM Weekly Buzz: GH Wins FDA Nod; NMPA Green Lights HCM; MDT To Acquire SPR ; BIIB HALTS BIIB112 5/22/2026 10:47:39 AM EMA Accepts MAA Review For Regeneron's Otarmeni In Treating Genetic Hearing Loss 5/22/2026 10:16:42 AM Regeneron Reports Positive Phase 1/2 LINKER-AL2 Data For Lynozyfic In Treating Amyloidosis 5/22/2026 9:12:57 AM Regeneron Pharmaceuticals's Genetic Hearing Loss Drug Wins EMA Filing Acceptance 5/22/2026 8:10:44 AM Regeneron Seeks European Approval For Otarmeni For Hearing Loss Gene Therapy 5/22/2026 7:25:52 AM Regeneron Reports Positive Results For Lynozyfic In AL Amyloidosis Trial 5/22/2026 1:55:16 AM Regeneron's Lynozyfic Shows Deep, Rapid Responses In Phase 1/2 LINKER-AL2 AL Amyloidosis Trial 5/21/2026 9:16:53 PM Regeneron Falls 11% Despite New Multi-Billion Dollar Drug Collaboration 5/18/2026 10:01:31 AM Regeneron Announces Strategic Collaboration With Parabilis Medicines On Antibody-Helicon Conjugates 5/18/2026 8:39:38 AM Morning Market Movers: SBFM, GOVX, HCAI, RAMP See Big Swings 5/18/2026 8:24:54 AM Regeneron Partners With Parabilis For Advancing Antibody-Helicon Conjugates 5/18/2026 7:44:47 AM Regeneron Partners With Parabilis On Novel Therapeutic Candidates 5/18/2026 7:07:33 AM. 1 2 Next » (https://www.rttnews.com/) Sat. Aug 15, 2026 | ||
| 2 (3) Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals This week's global biopharma sector roundup captured a mix of regulatory wins, restructuring activities, deals that expanded company pipelines, and clinical trial readouts. (https://www.rttnews.com/) Sat. Aug 15, 2026 | ||
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA